Diabetes vaccine nears decisive trial – could enable early submission
Within the coming few months, Swedish biotech firm Diamyd Medical will receive intermediate phase trial data on an experimental vaccine against type 1 diabetes. A Danish doctor says the matter is "extremely interesting."
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL FRANK CHRISTENSEN & IDA JACOBSEN
Excitement is peaking at the Stockholm-based biotech firm, Diamyd Medical, which is developing an experimental vaccine against autoimmune type 1 diabetes.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
